Correction: Chua et al. Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore. Cancers 2023, 15, 1812
,
,
,
,
and
1
Saw Swee Hock School of Public Health, National University of Singapore, 12 Science Drive 2, Singapore 117549, Singapore
2
Health Economics and Outcomes Research, Becton Dickinson Holdings Pte. Ltd., 2 International Business Park Road, The Strategy #08-08, Singapore 609930, Singapore
3
Division of Gynaecologic Oncology, Department of Obstetrics and Gynecology, National University Hospital, 5 Lower Kent Ridge Rd., Singapore 119074, Singapore
4
Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore
The authors wish to revise two words in Table 1 row 3, and the first paragraph of Section 2.3 of this article [1] that were overlooked in the final proofreading.
Table 1 row 3: “follow-up adherence” should be read as “follow-up non-adherence”; Section 2.3: the gross domestic product per capita in Singapore in 2021 should read “SGD 97,798” instead of “USD 97,798”.
This is the corrected paragraph:
Table 1.
Inputs for the model.
Table 1.
Inputs for the model.
Input
Base Case
Lower Limit
Upper Limit
Distribution
Reference
Number eligible
1,037,598
-
-
-
[27,28]
Screening coverage
48.2%
45.8%
50.7%
Beta
[30]
Follow-up non-adherence *
25.0%
0%
40%
-
[28] †
Clinical inputs
hrHPV
Prevalence
9.2%
7.9%
10.5%
Beta
[28]
% non-HPV16/18
80.8%
70.3%
83.0%
Beta
[28]
% Group B
56.6%
51.0%
61.0%
Beta
[41]
% NILM
56.1%
-
-
-
[42]
ASCUS among:
Group B
31.8%
-
-
-
[42]
Group A
40.6%
-
-
-
[42]
CIN1 regressing in 1 year
60.0%
45.0%
73.0%
Beta
[43]
Cancers among:
CIN2+ diagnosis
2.6%
2.3%
2.9%
Beta
[44]
CIN2+ of Group B with ASCUS
2.6%
0.0%
10.0%
-
[44,45,46,47]
CIN2+ risk with:
Group B with ASCUS
6.1%
2.6%
9.5%
Beta
[45,46,47,48]
Group A with ASCUS
14.2%
-
-
-
[48]
HPV16/18
21.9%
-
-
-
[48]
Non-HPV16/18 with LSIL+
16.4%
-
-
-
[48]
PSGI at repeat screening
57.1%
54.2%
60.1%
Beta
[49,50,51]
hrHPV 1 yr persistence
43.3%
41.8%
44.8%
Beta
[52]
HSIL/ASC-H 1 year post CIN1/negative for CIN
6.7%
5.7%
7.7%
Beta
[53]
ASCUS+/HPV+ 2 years post CIN1/negative for CIN
15.4%
13.8%
17.1%
Beta
[28]
Proportion stage I cancer
40.8%
-
-
-
[54]
Proportion stage II cancer
24.4%
-
-
-
[54]
Proportion stage III cancer
18.1%
-
-
-
[54]
Proportion stage IV cancer
16.7%
-
-
-
[54]
10-year cancer survival
45.4%
-
-
-
[40]
XGT repeat screenings
2
1
5
-
†
Annualized CIN2+ risk for
HPV genotype persistence
Same
5.7%
-
-
-
[55]
Change
1.9%
-
-
-
[55]
Regardless of genotype
3.3%
-
-
-
[55]
Multiplier for CIN2+ risk
1
0.7
1.38
Normal
†
Annualized CIN2+ risk for CIN1/negative for CIN
1 negative pap smear
1.1%
-
-
-
[56]
ASCUS/LSIL upon follow-up
2.1%
-
-
-
[56]
ASC-H upon follow-up
5.3%
-
-
-
[56]
HSIL+ upon follow-up
3.4%
-
-
-
[56]
Cost inputs SGD (USD)
Clinic visit
75 (89)
37 (44)
113 (134)
Normal
[34]
Cytology
79 (94)
39 (46)
119 (141)
Normal
[34]
HPV DNA (PGT)
115 (137)
57 (68)
173 (206)
Normal
[34]
CIN2/3 treatment
3662 (4354)
1832 (2178)
5492 (6530)
Normal
[34]
Colposcopy
350 (416)
174 (207)
526 (625)
Normal
[34]
Biopsy
500 (595)
250 (297)
750 (892)
Normal
[34]
Colposcopies with biopsies
8%
-
-
-
†
Stage I cancer treatment
28,350 (33,710)
14,176 (16,856)
42,524 (50,564)
-
[34]
Stage II cancer treatment
34,568 (41,103)
17,284 (20,552)
51,852 (61,655)
-
[34]
Stage III cancer treatment
34,568 (41,103)
17,284 (20,552)
51,852 (61,655)
-
[34]
Stage IV cancer line 1 treatment
43,016 (51,149)
21,508 (25,574)
64,524 (76,723)
-
[34]
Stage IV cancer line 2 treatment
75,552 (89,836)
37,776 (44,918)
113,328 (134,754)
-
[34]
Cancer treatment ‡
37,227 (44,265)
29,781 (35,412)
44,672 (53,118)
Normal
Calculated
XGT cost factor
1.15
1.00
1.30
-
†
Utility
Screening
0.980
0.970
0.990
-
[34]
Colposcopy normal results
0.950
0.924
0.976
-
[34]
CIN1
0.910
0.888
0.954
-
[34]
CIN2/3
0.870
0.804
0.936
-
[34]
Cancer Stage I
0.650
0.490
0.810
-
[34]
Cancer Stage II/III
0.560
0.420
0.700
-
[34]
Cancer Stage IV
0.480
0.360
0.600
-
[34]
Cancer stage I survivor
0.970
0.730
0.990
-
[34]
Cancer stage II/III survivor
0.900
0.680
0.990
-
[34]
Cancer stage IV survivor
0.620
0.470
0.780
-
[34]
QALY loss
Screening
0.000769
0.000384
0.00115
Normal
Calculated
CIN1 or negative for CIN1
0.00538
0.00269
0.00723
Normal
Calculated
CIN2/3
0.0200
0.00985
0.0302
Normal
Calculated
Cancer treatment ‡
0.0930
0.0640
0.121
Normal
Calculated
Average lifetime QALY loss for cancer ‡
18.7
14.9
22.4
Normal
Calculated
* repeat screening, post-colposcopy for CIN1/negative for CIN; † assumption; ‡ weighted by stage. Abbreviations: ASCUS: atypical squamous cells of undetermined significance; ASC-H: atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion; CIN: cervical intraepithelial neoplasia; hrHPV: human papillomavirus genotypes; HSIL: high-grade squamous intraepithelial lesion; PGT: HPV partial genotyping; NILM: negative for intraepithelial lesion or malignancy; XGT: HPV extended genotyping.
The total cost and QALY loss with XGT were compared to PGT. The difference in costs divided by the difference in QALY loss provided the incremental cost-effective ratio (ICER). All costs and QALY losses were discounted at 3.0% annually, in line with ACE recommendations [57]. The cost-effectiveness threshold was taken as SGD 100,000 (USD 118,906), comparable to the gross domestic product per capita in Singapore in 2021 (SGD 97,798) [58].
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.
Reference
Chua, B.; Lim, L.M.; Ng, J.S.Y.; Ma, Y.; Wee, H.L.; Caro, J.J. Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore. Cancers2023, 15, 1812. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.